• About Us
  • Science
    • Vaccines
    • Antibodies
  • Our Pipeline
  • Investors
    • Share Info
    • Financial Info
    • Documents & Presentations
    • Company Profile
    • Advisors
    • Corporate Governance
    • 2024 Capital Raise
  • Resources
    • News
    • Publications
  • Contact Us
    • Find a trial
    • Become an Investigator

15th Annual Protein & Antibody Summit Europe (PEGS), Lisbon, November 2023

by admin | Nov 30, 2023 | Antibodies, Glymab

GlyMabs® for T cell redirection

Result of 2023 Annual General Meeting

by admin | Nov 30, 2023 | Latest News, Regulatory News

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

Update on SCOPE trial

by admin | Nov 28, 2023 | Latest News, Regulatory News, SCIB1

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

Efficacy and safety results from the open-label Phase 2 SCOPE trial

by admin | Nov 17, 2023 | Immunobody, Vaccines

Heather Shaw, Poulam Patel, Miranda Payne, Satish Kumar, Sarah Danson, Dennis Hadjiyiannakis, Clare Barlow, Martin Highley, Amna Sheri, Amanda Fitzpatrick, Ioannis Karydis, Maria Marples, Robert Miller, Fayaz Master and Lindy Durrant

Scancell presents positive data from the first stage in its Phase 2 SCOPE trial at the 20th International Congress of the Society for Melanoma Research

by admin | Nov 10, 2023 | Immunobody, Latest News, Regulatory News, SCIB1

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!
« Older Entries

Recent Posts

  • Investor Update: 24 April 2025
  • Scancell’s new partnership with the NHS Vaccine Launch Pad (CLVP) March 2025
  • Partnership with NHS Cancer Vaccine Launch Pad Enabling Fast-Tracked Access for Melanoma Patients
  • Scancell to Present Clinical Data from the Ongoing Phase 2 SCOPE Trial of SCIB1 at 2025 AACR Annual Meeting
  • AACR 10 (American Association for Cancer Research), February 2025, Los Angeles, California

Recent Comments

No comments to show.

Scancell is focused on developing novel immunotherapies for the treatment of cancer and was founded in 1996 based on research led by Professor Lindy Durrant at the University of Nottingham in the UK.

  • Follow
  • Follow

About Us
Leadership Team
Science
Our Pipeline
News
Contact Us
Find a Trial
Become an Investigator

VACCINES

ImmunoBody®
Moditope®

ANTIBODIES

GlyMab®
AvidiMab®

Investors
Company Profile
Advisors
Corporate Governance
Documents & Presentations
Share Information
Financial Information

Copyright © 2025 Scancell | Website Designed & Developed by Identity Creative | Privacy & Cookie Policy